title: Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
abstract: OBJECTIVE
  The aim of the present study was to explore the effects of three different types of alpha-1 adrenoceptor blockers (α1-blocker) on lower urinary tract symptoms (LUTS), erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in patients with benign prostatic hyperplasia.
  
  
  METHODS
  A total of 136 male LUTS patients aged 50-80 years with International Prostate Symptom Score (IPSS) ≥8 were enrolled. They were divided into three groups. Group S received silodosin at 4 mg twice a day; group T received tamsulosin at 0.2 mg once a day; and group N received naftopidil at 50 mg once a day. Assessment included IPSS, quality of life indexes (QOL), International Index of Erectile Function (IIEF-5), an ejaculation questionnaire, Qmax and post-void residual urine volume (PVR). These parameters were recorded at baseline, and at 1 and 3 months after treatment had ended.
  
  
  RESULTS
  Mean IPSS and Qmax significantly improved after treatment in all groups without any significant difference among them. As for the IIEF-5 score, only group N significantly improved at 1 and 3 months. After treatment, 2.6 and 2.4% of patients complained of a de novo reduced volume of ejaculation in both groups T and N, respectively. Ten out of 41 patients (24.4%) complained of a total absence of antegrade ejaculation in group S after treatment.
  
  
  CONCLUSIONS
  All three types of α1-blockers provided an objective and subjective improvement of LUTS in the present study population. However, erectile function only improved in patients treated with naftopidil and a higher rate of EjD was observed in those receiving silodosin. Because of their variable effects, we should consider the sexual dimension when prescribing α1-blockers for LUTS.
authors.affiliation: Department of Urology, Kawasaki Medical School, Kurashiki, Okayama, Japan. uroyoko@med.kawasaki-m.ac.jp
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Ryoei
authors.initials: R
authors.lastname: Hara
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Fukumoto
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Fujii
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Jo
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Miyaji
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nagai
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sone
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D000369:Aged, 80 and over; D004542:Ejaculation / Q000187:drug effects; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects; D017060:Patient Satisfaction; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects; D011795:Surveys and Questionnaires; D000077409:Tamsulosin; D014554:Urination / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D007211:Indoles; D009281:Naphthalenes; D010879:Piperazines; D013449:Sulfonamides; C095285:silodosin; D000077409:Tamsulosin; C064357:naftopidil